ArticleThe oncologist2025

Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience.

Paulina Marell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.